Conclusions
1 evidence topic · 13 sources
Summary
- Tumor hyperinsulinism comprises insulinoma, with a population-based incidence of 0.6 to 4 cases per million per year in the studies identified, and non-islet cell tumor hypoglycemia, for which no population-based estimate exists. Survival is reduced in metastatic or malignant insulinoma (median 3.4 years with metastases in a Finnish nationwide cohort), and refractory hypoglycemia in these patients is associated with prolonged hospitalization and deferral of tumor-directed therapy.
- Current therapies have documented limitations: surgery is curative for most localized insulinomas but carries operative morbidity, diazoxide and somatostatin analogs control hypoglycemia in a proportion of patients with insulinoma and are described as ineffective in NICTH, and tumor-directed therapies for malignant disease do not directly treat hypoglycemia according to the manufacturer.
- The efficacy evidence for ersodetug in tumor hyperinsulinism consists of preliminary, unpublished results from the single-arm, open-label upLIFT trial (13 responders among 16 participants, with at least 9 required for statistical significance; final results pending) and a retrospective case series of 8 individuals with no control group. The randomized sunRIZE trial in congenital hyperinsulinism did not meet its primary or key secondary endpoint.
- The safety data come mostly from the congenital hyperinsulinism trials and include serious hypersensitivity reactions (overall incidence approximately 2% across the clinical trials) and hypertrichosis (about 35% of ersodetug-treated sunRIZE participants). No drug-related serious adverse events were reported in the tumor hyperinsulinism case series or, to date, in upLIFT.
- Ersodetug is investigational, with a biologics license application planned for mid-2027, and has no price; no budget impact model or economic evaluation has been published.